Acadia Pharmaceuticals Inc.
$27.54
$0.78 (+2.91%)
$26.66Day Range$27.60
Key Statistics
Market Cap
$4.61B
Shares Outstanding
172.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 27, 2004
Round Lot
100
Locale
US
Trading Data
Day Open
$26.75
Day High
$27.60
Day Low
$26.66
Volume
1.41M
VWAP
$27.41
Prev Close
$26.76
Transactions
--
Acc. Volume
--
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
PHARMACEUTICAL PREPARATIONSSIC 2834798 employees12830 EL CAMINO REAL, SAN DIEGO, CA, 92130858-558-2871IPO May 27, 2004US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001070494
- Composite FIGI
- BBG000BHG9K0
- Share Class FIGI
- BBG001SB06N3
- Ticker Root
- ACAD
- SIC Code
- 2834
About Acadia Pharmaceuticals Inc. (ACAD) Stock
Acadia Pharmaceuticals Inc. (ACAD) closed the 2026-09-16 session at $27.54, up 2.91% versus the previous close (+0.78). The stock opened at $26.75 and traded between $26.66 and $27.60 during that session. Session trading volume was 1.4M shares. The volume-weighted average price (VWAP) is $27.41.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Acadia Pharmaceuticals Inc. has a market capitalization of $4.61 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACAD is listed on the XNAS exchange. The company employs approximately 798 people. Acadia Pharmaceuticals Inc. is headquartered in SAN DIEGO, CA. The recorded listing date is 2004-05-27.
On this page you can find market ACAD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.